Evidence map›Paper›PMID 24714617›Full record

SynthesisPloS one2014

Serum uric acid levels in patients with Alzheimer's disease: a meta-analysis.

Xueping Chen, Xiaoyan Guo, Rui Huang, Yongping Chen, Zhenzhen Zheng, Huifang Shang

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Hyperuricemia, Gout, and the Brain-an Update.Current rheumatology reports · 2021
    Review
  6. Review
  7. Article
  8. Uric Acid and Hypertension: An Update With Recommendations.American journal of hypertension · 2020
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Association of amine biomarkers with incident dementia and Alzheimer's disease in the Framingham Study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2017
    Article
  17. Assessment of serum uric acid as risk factor for tauopathies.Journal of neural transmission (Vienna, Austria : 1996) · 2017
    Article
  18. Review
  19. Uric Acid and the Risk of Alzheimer's Disease: Is There an Association?American journal of Alzheimer's disease and other dementias · 2016
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Xueping ChenDepartment of Neurology, West China Hospital, Sichuan University, Chengdu Sichuan, China.
Xiaoyan GuoDepartment of Neurology, West China Hospital, Sichuan University, Chengdu Sichuan, China.
Rui HuangDepartment of Neurology, West China Hospital, Sichuan University, Chengdu Sichuan, China.
Yongping ChenDepartment of Neurology, West China Hospital, Sichuan University, Chengdu Sichuan, China.
Zhenzhen ZhengDepartment of Neurology, West China Hospital, Sichuan University, Chengdu Sichuan, China.
Huifang ShangDepartment of Neurology, West China Hospital, Sichuan University, Chengdu Sichuan, China.
Sichuan University · CNWest China Hospital of Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSerum uric acid (UA) could exert neuro-protective effects against Alzheimer's disease (AD) via its antioxidant capacities. Many studies investigated serum UA levels in AD patients, but to date, results from these observational studies are conflicting.

methodsWe conducted a meta-analysis to compare serum UA levels between AD patients and healthy controls by the random-effects model. Studies were identified by searching PubMed, ISI Web of Science, EMBASE, and the Cochrane library databases from 1966 through July 2013 using the Medical Subject Headings and keywords without restriction in languages. Only case-control studies were included if they had data on serum UA levels in AD patients and healthy controls. Begg's funnel plot and Egger's regression test were applied to assess the potential publication bias. Sensitivity analyses and meta-regression were conducted to explore possible explanations for heterogeneity.

resultsA total of 11 studies met the inclusion criteria including 2708 participants were abstracted. Serum UA levels were not significantly different in AD patients compared to healthy controls (standardized mean difference (SMD) = -0.50; 95% confidence interval (CI): -1.23 to 0.22). Little evidence of publication bias was observed. Sensitivity analyses showed that the combined SMD was consistent every time omitting any one study, except only one study which greatly influenced the overall results. Meta-regression showed that year of publication, race, sample size, and mean age were not significant sources of heterogeneity.

conclusionOur meta-analysis of case-control studies suggests that serum UA levels do not differ significantly in AD patients, but there may be a trend toward decreased UA in AD after an appropriate interpretation. More well-designed investigations are needed to demonstrate the potential change of serum UA levels in AD patients.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseFemaleHumansMaleUric AcidUric Acid

Identifiers

PMID24714617
PMCPMC3979756
OpenAlexW2014788080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.